Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Coleman

The oncologist

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
The Oncologist|January 1, 1996
Modulating the Radiation ResponseColeman
The Oncologist|September 27, 2002
Emerging role of topotecan in front-line treatment of carcinoma of the ovaryRobert L Coleman
The Oncologist|October 2, 2004
Bisphosphonates: clinical experienceRobert E Coleman
The Oncologist|December 8, 2000
Management of bone metastasesR E Coleman
The Oncologist|April 24, 2010
The road not taken and choices in radiation oncologyC Norman Coleman, Eli Glatstein
The Oncologist|September 20, 2022
An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial CancerCara Mathews, Domenica Lorusso, Robert L Coleman, et al.
The Oncologist|February 15, 2005
The role of mitoxantrone in the treatment of indolent lymphomasFredrick Hagemeister, Fernando Cabanillas, Morton Coleman, et al.
The Oncologist|October 5, 2007
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activityAllan Lipton, Richard J Cook, Pierre Major, et al.
The Oncologist|January 18, 2007
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patientsRobert L Coleman, Alan Gordon, James Barter, et al.
The Oncologist|February 8, 2024
Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical TrialsMuhammad Zaki Hidayatullah Fadlullah, Ching-Nung Lin, Samuel Coleman, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
The Oncologist|January 1, 1996
Modulating the Radiation ResponseColeman
The Oncologist|September 27, 2002
Emerging role of topotecan in front-line treatment of carcinoma of the ovaryRobert L Coleman
The Oncologist|October 2, 2004
Bisphosphonates: clinical experienceRobert E Coleman
The Oncologist|December 8, 2000
Management of bone metastasesR E Coleman
The Oncologist|April 24, 2010
The road not taken and choices in radiation oncologyC Norman Coleman, Eli Glatstein
The Oncologist|September 20, 2022
An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial CancerCara Mathews, Domenica Lorusso, Robert L Coleman, et al.
The Oncologist|February 15, 2005
The role of mitoxantrone in the treatment of indolent lymphomasFredrick Hagemeister, Fernando Cabanillas, Morton Coleman, et al.
The Oncologist|October 5, 2007
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activityAllan Lipton, Richard J Cook, Pierre Major, et al.
The Oncologist|January 18, 2007
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patientsRobert L Coleman, Alan Gordon, James Barter, et al.
The Oncologist|February 8, 2024
Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical TrialsMuhammad Zaki Hidayatullah Fadlullah, Ching-Nung Lin, Samuel Coleman, et al.
Pageof 2